Drug Trial Radar · NCT03529084
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Last checked: Nov 20, 2026Latest source record: Nov 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 24, 2018
Primary completion
Aug 13, 2020
Study completion Jun 3, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, open label, randomized controlled multi-center global study designed to evaluate the safety and efficacy of single agent nazartinib (EGF816) compared with investigator's choice (erlotinib or gefitinib) in patients with locally advanced or metastatic NSCLC who are treatment naïve and whose tumors harbor EGFR activating mutations (L858R or ex19del).
Conditions
- Carcinoma, Non-small Cell Lung
Interventions
EFG816Drug
It will be administered orally daily.
erlotinib or gefitinibDrug
Investigator's choice between erlotinib or gefitinib. These will be locally sourced. Erlotinib will be administered orally daily. Gefitinib will be administered orally daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Blinded independent review committee (BIRC)Time frame: Approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.